Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Generate Biomedicines, Inc. (GENB : NSDQ)
 
 • Company Description   
Generate Biomedicines Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. Generate Biomedicines Inc. is based in SOMERVILLE, Mass.

Number of Employees: 312

 
 • Price / Volume Information   
Yesterday's Closing Price: $12.41 Daily Weekly Monthly
20 Day Moving Average: 970,112 shares
Shares Outstanding: 128.35 (millions)
Market Capitalization: $1,592.85 (millions)
Beta:
52 Week High: $22.67
52 Week Low: $11.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -22.39% -21.57%
12 Week -11.55% -13.71%
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
101 SOUTH STREET SUITE 900
-
SOMERVILLE,MA 02143
USA
ph: 888-469-0055
fax: -
investors@generatebiomedicines.com http://www.generatebiomedicines.com
 
 • General Corporate Information   
Officers
Michael Nally - Chief Executive Officer
Noubar B. Afeyan - Chairperson
Jason Silvers - President and Chief Financial Officer
Frances Arnold - Director
Stephane Bancel - Director

Peer Information
Generate Biomedicines, Inc. (CORR.)
Generate Biomedicines, Inc. (RSPI)
Generate Biomedicines, Inc. (CGXP)
Generate Biomedicines, Inc. (BGEN)
Generate Biomedicines, Inc. (GTBP)
Generate Biomedicines, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 370920100
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/05/26
Share - Related Items
Shares Outstanding: 128.35
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $1,592.85 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.53 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.29 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/05/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.49
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 51.40%
Sales Growth
vs. Year Ago Period: -37.67%
vs. Previous Quarter: -12.60%
ROE
09/30/26 - -
06/30/26 - -
03/31/26 - -
ROA
09/30/26 - -
06/30/26 - -
03/31/26 - -
Current Ratio
09/30/26 - -
06/30/26 - 8.30
03/31/26 - 9.17
Quick Ratio
09/30/26 - -
06/30/26 - 8.30
03/31/26 - 9.17
Operating Margin
09/30/26 - -
06/30/26 - -
03/31/26 - -
Net Margin
09/30/26 - -
06/30/26 - -
03/31/26 - -
Pre-Tax Margin
09/30/26 - -
06/30/26 - -
03/31/26 - -
Book Value
09/30/26 - -
06/30/26 - 3.55
03/31/26 - 4.02
Inventory Turnover
09/30/26 - -
06/30/26 - -
03/31/26 - -
Debt-to-Equity
09/30/26 - -
06/30/26 - 0.00
03/31/26 - 0.00
Debt-to-Capital
09/30/26 - -
06/30/26 - 0.30
03/31/26 - 0.43
 

Powered by Zacks Investment Research ©